



Biocon Biologics to acquire Viatrix' Biosimilars Business

28 February 2022




Safe Harbor Statement

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Biocon has consistently unlocked value over four decades

Biocon has benefited from transformational moves every decade



Mapping Biocon Biologics capabilities as a biosimilars company

Emerging Markets

Developed Markets

Biosimilar Value Chain

PRODUCT DEVELOPMENT



CLINICAL TRIALS



REGULATORY



MANUFACTURING



SUPPLY CHAIN



COMMERCIALIZATION



Viатris' biosimilars business adds financial depth and commercial capabilities



Viатris to provide commercial and transition services for an expected two-year period, at cost plus \$44m p.a.

¹ BBL estimates of Viатris' business

Considerations to Viatrix

1	Cash Payment of \$2b at Closing <i>(\$50m payment from Viatrix for capex funding)</i>	\$1,950m	Total considerations at \$2.3b in cash and \$1b of CCPS
2	Compulsorily Convertible Preference Shares <i>(represents an equity stake of at least 12.9%)</i>	\$1,000m	
3	Deferred consideration <i>(payment due in FY25)</i>	\$160m	
4	Option to acquire bAflibercept <i>(payment due in FY25)</i>	\$175m	

Viatrix will have one nominee on the Board of Biocon Biologics

Financing the acquisition



Biocon Biologics to be a fully integrated global biosimilars company...



CURRENT

Emerging Markets

Developed Markets



POST ACQUISITION

Global markets

Biosimilar Value Chain

PRODUCT DEVELOPMENT



CLINICAL TRIALS



REGULATORY



MANUFACTURING




SUPPLY CHAIN



COMMERCIALIZATION



...with a comprehensive portfolio providing scale and future growth



7 Commercialized in Global Markets

20 Biosimilars in Portfolio

Building an organization for the next decade

Key investment highlights

- 1 Fully integrated global biosimilars company (lab to market)
- 2 Strong commercial presence in global markets
- 3 Comprehensive portfolio of biosimilars and vaccines
- 4 Global scale biologics manufacturing capacity
- 5 Experienced management team with strong execution capabilities
- 6 Strong business financials enabling long-term growth

Q&A

